Pharmaceuticals

"Pharmaceuticals" Main

Latest Morning Briefing Stories

Black Men’s Blood Pressure Is Cut Along With Their Hair

KFF Health News Original

A new study shows that educational sessions about high blood pressure at African American barbershops, coupled with prescribing and helping to manage medication, reduced hypertension rates significantly.

Campus Voices: Should Student Health Centers Offer Abortion Pills?

KFF Health News Original

California lawmakers are considering a bill that would require student health centers at all of the state’s four-year public universities to carry the abortion pill. Students at campuses across the state sounded off on the proposal.

Podcast: KHN’s ‘What The Health?’ HHS Leaders Take To The Stump

KFF Health News Original

In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico and new podcast panelist Anna Edney of Bloomberg News discuss this week’s spate of speeches by the leaders of the Department of Health and Human Services. They also discuss the slow progress on health legislation on Capitol Hill intended to fund the government and stabilize the individual insurance market. Plus, for extra credit, the panelists offer their favorite health policy stories of the week.

Of ‘Miracles’ And Money: Why Hemophilia Drugs Are So Expensive

KFF Health News Original

The market is flooded with 28 different medications for just 20,000 patients with the hereditary bleeding disorder. Yet intense competition hasn’t worked to bring costs down. Sales amount to $4.6 billion annually in the U.S.

Jury’s In: Opioids Are Not Better Than Other Medicines For Chronic Pain

KFF Health News Original

A new study followed patients with severe chronic pain for a year and found that opioids relieved pain and increased function no better than common drugs like acetaminophen and lidocaine. But the opioids carry the risk of more serious side effects, including addiction and death.

Para abaratar el costo de los medicamentos, estados quieren importarlos de Canadá

KFF Health News Original

Algunos estados buscan impulsar al gobierno federal para que allane el camino para comprar stocks de medicamentos en Canadá con el fin de abaratar los costos y ahorrarle dinero a las arcas estatales.

KHN On NPR: The Uniquely American Problem Of High Prescription Drug Costs

KFF Health News Original

Kaiser Health News Editor-in-Chief Elisabeth Rosenthal discusses drug costs with Scott Simon, the host of NPR’s Weekend Edition. Listen to the broadcast and read a transcript of that conversation.

Podcast: KHN’s ‘What The Health?’ There’s A Really Big Health Bill In That Budget Deal

KFF Health News Original

In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Alice Ollstein of Talking Points Memo, Joanne Kenen of Politico and Margot Sanger-Katz of The New York Times discuss the health policy changes included in the just-concluded bipartisan budget deal on Capitol Hill. The panelists also talk about the final enrollment numbers for individual insurance purchased under the Affordable Care Act, and possible drug price proposals in President Donald Trump’s upcoming budget. Plus, Rovner interviews Andy Slavitt, who this week launched a health care advocacy group called “The United States of Care.”

Podcast: KHN’s ‘What The Health?’ The State Of The (Health) Union

KFF Health News Original

In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Alice Ollstein of Talking Points Memo and Julie Appleby and Sarah Jane Tribble of Kaiser Health News discuss President Donald Trump’s promises to reduce drug prices in his first State of the Union Address. The panelists also discuss the departure of the director of the Centers for Disease Control and Prevention after conflict-of-interest reports and the efforts by some states to flout the Affordable Care Act.

University Under Fire For Off-The-Grid Herpes Vaccine Experiments

KFF Health News Original

Southern Illinois University’s medical school has halted all herpes research, one of its most high-profile projects, amid growing controversy over a researcher’s unauthorized methods offshore and in the U.S.